News Mar 26, 2024 Top Stories from Western Switzerland (March 2024) From innovative approaches in cardiac care and sustainable plastics to enhancing spinal cord injury therapies and advancing virtual power plants,...
News Feb 29, 2024 Top Stories from Western Switzerland (February 2024) From significant strides in semiconductor innovation and breakthroughs in medical research to strategic advancements in fintech and medtech secto...
News Jan 30, 2024 Top Stories from Western Switzerland (January 2024) From groundbreaking advancements in agrifood and robotics to strategic economic reforms and pioneering research in space and medicine, discover W...
News Dec 19, 2023 Top Stories from Western Switzerland (October-December 2023) From achieving top rankings in global innovation to making significant advancements in healthcare and technology, discover Western Switzerland's ...
News Sep 29, 2023 Top Stories from Western Switzerland (July-September 2023) From spearheading eco-innovative solutions to pioneering breakthroughs in solar technology, cancer research, sustainable shipping, and the realms...
Aktuell Oct 17, 2022 Escientia Switzerland wird zu Primopus Die indische Deccan Fine Chemicals übernimmt Escientia Switzerland und gibt ihr einen neuen Namen: Primopus AG. Die Schweizer Niederlassung der n...
News Apr 26, 2023 Western Switzerland’s biotech sector flourishes amidst global challenges Western Switzerland's biotech industry continues to thrive, displaying resilience amidst global challenges. The region's unique ecosystem fosters...
News Jul 04, 2023 Top Stories from Western Switzerland (April-June 2023) From space exploration to medical breakthroughs and advancements in education and industry, discover Western Switzerland's top stories from April...
Press Release Jun 29, 2023 Switzerland is the world's digital vault Switzerland is successfully positioning itself as a pioneer in safeguarding digital assets and strengthening its role in global wealth manag...
News May 24, 2023 Latest research shows 20% of European biotechs now headquartered in Switzerland Press release New research conducted by IQVIA and recently published in the 2023 Swiss Biotech Report shows that 20% of European biotech companies are now head...
Commercial HQ in Switzerl... May 09, 2023 Commercial HQ in Switzerland Setting up Your Commercial HQ in Switzerland: The Key to European Market Success: Are you a pharmaceutical company seeking to access the European...
News Jan 26, 2023 How the FTX Crash Shows Switzerland’s Resilience and Potential for Blockchain Companies After reaching a peak market value in 2021, cryptocurrencies have spent the better part of 2022 in a tailspin generated by scandal and financial ...
Medienmitteilungen Mar 08, 2022 Switzerland Global Enterprise und Schweiz Tourismus holen innovative Firmen in die Schweiz Die Schweiz ist als Innovationsstandort prädestiniert für die Entwicklung neuer Geschäftsmodelle mit Zukunftstechnologien. Eine wichtige Rolle sp...
Expertise Feb 08, 2023 Switzerland: A Global Leader in Blockchain Education and Research Switzerland is renowned for its highly skilled and international workforce and is ranked first in INSEAD Global Talent Competitiveness Index for ...
Communiqués de Presse Apr 06, 2022 Switzerland Global Enterprise et Suisse Tourisme invitent des Enterprises d'avant-garde à s'établir en Suisse Berceau de quantité d’innovations, la Suisse est propice au développement de nouveaux modèles d’affaires impliquant les technologies d’avenir. L’...
Success stories Feb 08, 2023 “Stability and openness – this is what we appreciate about Switzerland” Ledger The French company Ledger is the world-wide leader in security for crypto assets. With the help of the Swiss Business Hub France, the company has...
Comunicati Stampa Mar 10, 2022 Switzerland Global Enterprise e Svizzera Turismo invitano aziende innovative in Svizzera La Svizzera, nel suo ruolo di piazza d’innovazione, è ideale per lo sviluppo di nuovi modelli di business con tecnologie del futuro. Un ruolo imp...
Aktuell May 22, 2024 CUTISS erhält von Investoren 25 Millionen Franken CUTISS hat eine erste Serie C-Finanzierung mit 25 Millionen Franken abgeschlossen. Damit kann das Life Science-Unternehmen der regenerativen Medi...